News Quantified

SNDX – syndax pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Syndax Pharma: Continuing Execution In AML [Seeking Alpha]

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

13.3%

BEAT

21.1%

BEAT

-22.6%

BEAT

-3.1%

MISS

Form 8-K Syndax Pharmaceuticals For: Dec 18

Form 4 Syndax Pharmaceuticals For: Dec 01 Filed by: Goldan Keith A.

Form 10-Q Syndax Pharmaceuticals For: Sep 30

Form 8-K Syndax Pharmaceuticals For: Nov 03

Form 8-K Syndax Pharmaceuticals For: Oct 24

Top News Gainers

4/27 Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias 69.4%

5/6 Form 8-K Syndax Pharmaceuticals For: May 06 35.6%

1/31 Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million 34.0%

3/3 Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update 21.7%

2/4 Form 8-K Syndax Pharmaceuticals For: Jan 30 17.6%

4/14 Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting 12.6%

3/24 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 11.1%

11/8 Syndax Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 8.1%

10/11 Form 4 Syndax Pharmaceuticals For: Oct 10 Filed by: Morrison Briggs 6.7%

8/7 Form S-8 Syndax Pharmaceuticals 6.3%

Top News Decliners

2/15 Form 4 Syndax Pharmaceuticals For: Feb 12 Filed by: Legault Pierre -8.5%

2/4 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -7.6%

10/7 Form 8-K Syndax Pharmaceuticals For: Oct 07 -6.1%

4/30 Form 8-K Syndax Pharmaceuticals For: Apr 30 -5.9%

8/9 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.8%

3/12 Syndax Pharmaceuticals Inc (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc from to . -5.7%

8/13 Syndax Pharmaceuticals (SNDX) Investor Presentation - Slideshow [Seeking Alpha] -5.0%

2/6 Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock Inc. -4.8%

2/20 Form 8-K Syndax Pharmaceuticals For: Feb 12 -4.3%

8/28 Syndax Announces Participation at Four Upcoming Investor Conferences -4.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day